Kineticos and Orthobond Join Forces to Combat Bacterial Infection
Kineticos Life Sciences Teams Up with Orthobond
Kineticos Life Sciences has announced an exciting partnership with Orthobond, a frontrunner in innovative antibacterial technologies. This collaboration is facilitated through the Kineticos AMR Accelerator Fund I, which is actively seeking to support groundbreaking advancements in healthcare. Kineticos aims to make a significant impact in the fight against antimicrobial resistance, an escalating global health concern.
Investment and Growth for Orthobond
Orthobond has recently secured approval for their FDA De Novo application related to their pioneering technology, Ostaguard™, which provides an antibacterial non-drug eluting solution for spinal implants. This monumental achievement reflects Orthobond’s commitment to enhancing patient safety during surgical procedures. The financial backing from Kineticos will further empower Orthobond as they prepare to commercialize Ostaguard™ and expand its applications beyond spinal surgery.
Commitment to Innovation in Healthcare
The meticulous efforts of Orthobond in developing antibacterial surfaces for medical devices signify a crucial step toward fighting bacterial infections in surgical settings. Mark Bamforth, a member of the KAMRA Fund I General Partnership, expressed his enthusiasm about joining forces with Orthobond. He emphasized the importance of addressing bacterial contamination during implant surgeries, thus benefiting patients worldwide.
Insights from Orthobond’s Leadership
David Nichols, CEO of Orthobond, also shared his excitement regarding the partnership with Kineticos. He highlighted the potential of Ostaguard™ in becoming the gold standard for implantable devices, providing a safer option for patients. The expertise and guidance from Kineticos will be vital as Orthobond undertakes further research and evidence-building around Ostaguard™.
Strategic Advisory Role
In a noteworthy addition to this partnership, Steve Favaloro, Strategic Advisor to the KAMRA Fund I, will join the board of directors at Orthobond. With extensive experience in the biotech sector, Favaloro emphasizes the potential impact of Orthobond’s technology on public health. His expertise will guide the company's growth trajectory and its mission to address antimicrobial resistance on a global scale.
Understanding Kineticos Life Sciences
Kineticos Life Sciences is dedicated to creating A World Without AMR™. By collaborating with visionary entrepreneurs in the life sciences, Kineticos fosters innovation aimed at resolving significant medical challenges. Their investment in Orthobond exemplifies their commitment to enhancing patient outcomes and pushing the boundaries of how diseases are treated.
Exploring the Future with Orthobond
Orthobond Corporation continues to make strides in surface technology, creating proprietary antibacterial surfaces suitable for various industries, including medical devices, automotive, and more. Their groundbreaking approach to permanently binding antibacterial technologies could revolutionize infection control, ensuring better health outcomes for patients across different settings.
Frequently Asked Questions
What is the main focus of the partnership between Kineticos and Orthobond?
The partnership primarily focuses on advancing innovative antibacterial technologies, particularly in the realm of medical devices, to combat antimicrobial resistance.
What technology has Orthobond developed?
Orthobond has developed Ostaguard™, an antibacterial non-drug eluting solution designed for spinal implants, receiving recent FDA approval.
Who is joining Orthobond's board of directors?
Steve Favaloro, Strategic Advisor to the KAMRA Fund I, will join Orthobond's board, bringing valuable biotech experience to the team.
How does Kineticos aim to impact healthcare?
Kineticos aims to disrupt traditional methods in drug development and disease diagnosis, improving patient outcomes across the board.
What sets Orthobond's technology apart?
Orthobond utilizes proprietary antibacterial surfaces that kill bacteria without the use of eluting antibiotics, providing a unique solution in infection prevention.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.